Nasdaq · CIK 0001280776
IMUX IMMUNIC, INC.
Insider trading from SEC Form 4. Last filing 24 d ago. Close $8.19 on Oct 9, 2026, +61% from the 52-week low and -52% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
IMUXOct 9, 2026 · close 8.19
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at IMMUNIC, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | Daniel Vitt CEO and Director buy | $12k 15,000 shares | +107% | +17% from low-60% from high | |
| 51Moderate | Jason Tardio President and COO buy | $9,884 12,512 shares | - | +17% from low-60% from high | |
| 53Moderate | Duane Nash Executive Chairman buy | $17k 20,000 shares | +125% | +22% from low-59% from high | |
| 51Moderate | Jason Tardio President and COO buy | $9,884 12,512 shares | - | +17% from low-60% from high | |
| 58Moderate | Daniel Vitt CEO and Director buy | $12k 15,000 shares | +107% | +17% from low-60% from high | |
| 56Moderate | Joerg Neermann director buy | $77k 100,000 shares | +100% | +17% from low-60% from high | |
| 58Moderate | Richard Alan Rudick director buy | $100k 143,075 shares | +164% | +11% from low-63% from high | |
| 60Notable | Glenn Whaley Chief Financial Officer buy | $32k 45,000 shares | +89% | +11% from low-63% from high | |
| 33Weak | Richard Alan Rudick director buy | $100k 87,300 shares | - | - |
Transactions
The last 60 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Robert Thorvald Nagel director | AGrant or award Stock Optionderivative | +25,370 | $0.00 | $0 | 25,370 | 24 d ago |
| Sep 16, 2026 | Bvf Partners L P/il director, other | AGrant or award Stock Optionderivativeindirect: See footnote | +25,370 | $0.00 | $0 | 25,370 | 24 d ago |
| Jul 16, 2025 | Jason Tardio President and COO | AGrant or award Stock Appreciation Rightderivative | +330,000 | $0.00 | $0 | 330,000 | Jul 18, 2025 |
| Jul 16, 2025 | Glenn Whaley Chief Financial Officer | AGrant or award Stock Appreciation Rightderivative | +280,000 | $0.00 | $0 | 280,000 | Jul 18, 2025 |
| Jul 16, 2025 | Andreas Muehler Chief Medical Officer | AGrant or award Stock Appreciation Rightderivative | +330,000 | $0.00 | $0 | 330,000 | Jul 18, 2025 |
| Jul 16, 2025 | Duane Nash Executive Chairman | AGrant or award Stock Appreciation Rightderivative | +315,000 | $0.00 | $0 | 315,000 | Jul 18, 2025 |
| Jul 16, 2025 | Daniel Vitt CEO and Director | AGrant or award Stock Appreciation Rightderivative | +860,000 | $0.00 | $0 | 860,000 | Jul 18, 2025 |
| Jul 16, 2025 | Jason Tardio President and COO | AGrant or award Stock Appreciation Rightderivative | +660,000 | $0.00 | $0 | 660,000 | Jul 18, 2025 |
| Jul 16, 2025 | Glenn Whaley Chief Financial Officer | AGrant or award Stock Appreciation Rightderivative | +560,000 | $0.00 | $0 | 560,000 | Jul 18, 2025 |
| Jul 16, 2025 | Andreas Muehler Chief Medical Officer | AGrant or award Stock Appreciation Rightderivative | +660,000 | $0.00 | $0 | 660,000 | Jul 18, 2025 |
| Jul 16, 2025 | Duane Nash Executive Chairman | AGrant or award Stock Appreciation Rightderivative | +630,000 | $0.00 | $0 | 630,000 | Jul 18, 2025 |
| Jul 16, 2025 | Daniel Vitt CEO and Director | AGrant or award Stock Appreciation Rightderivative | +1,720,000 | $0.00 | $0 | 1,720,000 | Jul 18, 2025 |
| Jul 16, 2025 | Glenn Whaley Chief Financial Officer | AGrant or award Stock Appreciation Rightderivative | +560,000 | $0.00 | $0 | 560,000 | Jul 18, 2025 |
| Jul 16, 2025 | Duane Nash Executive Chairman | AGrant or award Stock Appreciation Rightderivative | +630,000 | $0.00 | $0 | 630,000 | Jul 18, 2025 |
| Jul 16, 2025 | Daniel Vitt CEO and Director | AGrant or award Stock Appreciation Rightderivative | +1,720,000 | $0.00 | $0 | 1,720,000 | Jul 18, 2025 |
| Jul 16, 2025 | Jason Tardio President and COO | AGrant or award Stock Appreciation Rightderivative | +660,000 | $0.00 | $0 | 660,000 | Jul 18, 2025 |
| Jul 16, 2025 | Andreas Muehler Chief Medical Officer | AGrant or award Stock Appreciation Rightderivative | +660,000 | $0.00 | $0 | 660,000 | Jul 18, 2025 |
| Jul 16, 2025 | Daniel Vitt CEO and Director | AGrant or award Stock Appreciation Rightderivative | +860,000 | $0.00 | $0 | 860,000 | Jul 18, 2025 |
| Jul 16, 2025 | Andreas Muehler Chief Medical Officer | AGrant or award Stock Appreciation Rightderivative | +330,000 | $0.00 | $0 | 330,000 | Jul 18, 2025 |
| Jul 16, 2025 | Duane Nash Executive Chairman | AGrant or award Stock Appreciation Rightderivative | +315,000 | $0.00 | $0 | 315,000 | Jul 18, 2025 |
| Jul 16, 2025 | Glenn Whaley Chief Financial Officer | AGrant or award Stock Appreciation Rightderivative | +280,000 | $0.00 | $0 | 280,000 | Jul 18, 2025 |
| Jul 16, 2025 | Jason Tardio President and COO | AGrant or award Stock Appreciation Rightderivative | +330,000 | $0.00 | $0 | 330,000 | Jul 18, 2025 |
| Jul 16, 2025 | Glenn Whaley Chief Financial Officer | AGrant or award Stock Appreciation Rightderivative | +280,000 | $0.00 | $0 | 280,000 | Jul 18, 2025 |
| Jul 16, 2025 | Jason Tardio President and COO | AGrant or award Stock Appreciation Rightderivative | +330,000 | $0.00 | $0 | 330,000 | Jul 18, 2025 |
| Jul 16, 2025 | Duane Nash Executive Chairman | AGrant or award Stock Appreciation Rightderivative | +315,000 | $0.00 | $0 | 315,000 | Jul 18, 2025 |
| Jul 16, 2025 | Andreas Muehler Chief Medical Officer | AGrant or award Stock Appreciation Rightderivative | +330,000 | $0.00 | $0 | 330,000 | Jul 18, 2025 |
| Jul 16, 2025 | Daniel Vitt CEO and Director | AGrant or award Stock Appreciation Rightderivative | +860,000 | $0.00 | $0 | 860,000 | Jul 18, 2025 |
| Jun 5, 2025 | Jason Tardio President and COO | POpen-market purchase Common Stock | +12,512 | $0.79 | $9,884 | 12,512 | Jun 20, 2025 |
| Jun 4, 2025 | Daniel Vitt CEO and Director | POpen-market purchase Common Stock | +15,000 | $0.77 | $12k | 29,000 | Jun 20, 2025 |
| Jun 5, 2025 | Glenn Whaley Chief Financial Officer | AGrant or award Stock Optionderivative | +503,500 | $0.00 | $0 | 503,500 | Jun 20, 2025 |
| Jun 5, 2025 | Duane Nash Executive Chairman | AGrant or award Stock Optionderivative | +570,000 | $0.00 | $0 | 570,000 | Jun 20, 2025 |
| Jun 5, 2025 | Andreas Muehler Chief Medical Officer | AGrant or award Stock Optionderivative | +598,500 | $0.00 | $0 | 598,500 | Jun 20, 2025 |
| Jun 5, 2025 | Jason Tardio President and COO | AGrant or award Stock Optionderivative | +598,500 | $0.00 | $0 | 598,500 | Jun 20, 2025 |
| Jun 5, 2025 | Daniel Vitt CEO and Director | AGrant or award Stock Optionderivative | +1,558,000 | $0.00 | $0 | 1,558,000 | Jun 20, 2025 |
| Jun 13, 2025 | Duane Nash Executive Chairman | POpen-market purchase Common Stock | +20,000 | $0.83 | $17k | 36,032 | Jun 16, 2025 |
| Jun 5, 2025 | Andreas Muehler Chief Medical Officer | AGrant or award Stock Optionderivative | +595,000 | $0.00 | $0 | 595,000 | Jun 9, 2025 |
| Jun 5, 2025 | Simona Skerjanec director | AGrant or award Stock Optionderivative | +150,000 | $0.00 | $0 | 150,000 | Jun 9, 2025 |
| Jun 5, 2025 | Richard Alan Rudick director | AGrant or award Stock Optionderivative | +150,000 | $0.00 | $0 | 150,000 | Jun 9, 2025 |
| Jun 5, 2025 | Monika Maria Toernsen director | AGrant or award Stock Optionderivative | +150,000 | $0.00 | $0 | 150,000 | Jun 9, 2025 |
| Jun 5, 2025 | Jason Tardio President and COO | POpen-market purchase Common Stock | +12,512 | $0.79 | $9,884 | 12,512 | Jun 9, 2025 |
| Jun 5, 2025 | Joerg Neermann director | AGrant or award Stock Optionderivative | +150,000 | $0.00 | $0 | 150,000 | Jun 9, 2025 |
| Jun 5, 2025 | Glenn Whaley Chief Financial Officer | AGrant or award Stock Optionderivative | +503,000 | $0.00 | $0 | 503,000 | Jun 9, 2025 |
| Jun 5, 2025 | Duane Nash Executive Chairman | AGrant or award Stock Optionderivative | +560,000 | $0.00 | $0 | 560,000 | Jun 9, 2025 |
| Jun 5, 2025 | Barclay A Phillips director | AGrant or award Stock Optionderivative | +150,000 | $0.00 | $0 | 150,000 | Jun 9, 2025 |
| Jun 5, 2025 | Tamar D Howson director | AGrant or award Stock Optionderivative | +150,000 | $0.00 | $0 | 150,000 | Jun 9, 2025 |
| Jun 5, 2025 | Jason Tardio President and COO | AGrant or award Stock Optionderivative | +595,000 | $0.00 | $0 | 595,000 | Jun 9, 2025 |
| Jun 4, 2025 | Daniel Vitt CEO and Director | POpen-market purchase Common Stock | +15,000 | $0.77 | $12k | 29,000 | Jun 6, 2025 |
| Jun 5, 2025 | Daniel Vitt CEO and Director | AGrant or award Stock Optionderivative | +1,535,000 | $0.00 | $0 | 1,535,000 | Jun 6, 2025 |
| Jun 4, 2025 | Joerg Neermann director | POpen-market purchase Common Stock | +70,000 | $0.77 | $54k | 170,000 | Jun 5, 2025 |
| Jun 5, 2025 | Joerg Neermann director | POpen-market purchase Common Stock | +30,000 | $0.76 | $23k | 200,000 | Jun 5, 2025 |
| Jun 3, 2025 | Richard Alan Rudick director | POpen-market purchase Common Stock | +143,075 | $0.70 | $100k | 230,375 | Jun 4, 2025 |
| May 30, 2025 | Glenn Whaley Chief Financial Officer | AGrant or award Common Stock | +25,000 | $0.56 | $14k | 50,510 | Jun 4, 2025 |
| Jun 3, 2025 | Glenn Whaley Chief Financial Officer | POpen-market purchase Common Stock | +45,000 | $0.71 | $32k | 95,510 | Jun 4, 2025 |
| Dec 4, 2024 | Duane Nash Executive Chairman | AGrant or award Stock Optionderivative | +300,000 | $0.00 | $0 | 300,000 | Dec 9, 2024 |
| Dec 4, 2024 | Glenn Whaley Chief Financial Officer | AGrant or award Stock Optionderivative | +265,000 | $0.00 | $0 | 265,000 | Dec 6, 2024 |
| Dec 4, 2024 | Daniel Vitt CEO and Director | AGrant or award Stock Optionderivative | +820,000 | $0.00 | $0 | 820,000 | Dec 6, 2024 |
| Dec 4, 2024 | Jason Tardio President and COO | AGrant or award Stock Optionderivative | +157,500 | $0.00 | $0 | 157,500 | Dec 6, 2024 |
| Dec 4, 2024 | Andreas Muehler Chief Medical Officer | AGrant or award Stock Optionderivative | +315,000 | $0.00 | $0 | 315,000 | Dec 6, 2024 |
| Dec 4, 2024 | Duane Nash Executive Chairman | AGrant or award Stock Optionderivative | +300,000 | $0.00 | $0 | 300,000 | Dec 6, 2024 |
| Nov 12, 2024 | Richard Alan Rudick director | POpen-market purchase Common Stock | +87,300 | $1.15 | $100k | 87,300 | Nov 13, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Bvf Partners L P/ilother, owner, director
- Tamar D Howsondirector
- Andreas MuehlerChief Medical Officer
- Robert Thorvald Nageldirector
- Duane NashExecutive Chairman
- Joerg Neermanndirector
- Barclay A Phillipsdirector
- Richard Alan Rudickdirector
- Simona Skerjanecdirector
- Jason TardioPresident and COO
- Monika Maria Toernsendirector
- Daniel VittCEO and Director
- Glenn WhaleyChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.